Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 May;21(5):906-12.
doi: 10.1016/j.bbmt.2015.01.026. Epub 2015 Feb 7.

Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies

Amin M Alousi  1 , Jonathan E Brammer  2 , Rima M Saliba  2 , Borje Andersson  2 , Uday Popat  2 , Chitra Hosing  2 , Roy Jones  2 , Elizabeth J Shpall  2 , Issa Khouri  2 , Muzaffar Qazilbash  2 , Yago Nieto  2 , Nina Shah  2 , Sairah Ahmed  2 , Betul Oran  2 , Gheath Al Atrash  2 , Stefan Ciurea  2 , Partow Kebriaei  2 , Julianne Chen  2 , Gabriela Rondon  2 , Richard E Champlin  2
Affiliations
Clinical Trial

Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies

Amin M Alousi et al. Biol Blood Marrow Transplant. 2015 May.

Abstract

Graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (CY) after ablative HLA-matched bone marrow (BM) transplantation has been reported to have comparable rates of acute GVHD with an apparent reduction in chronic GVHD and infections when compared to historical prophylaxis with a calcineurin-inhibitor (CNI) and methotrexate (MTX). We conducted a phase II trial of post-transplantation CY (post-CY) after reduced-intensity conditioning (RIC) using intravenous busulfan (area under the curve of 4000 micromolar minute), fludarabine (40 mg/m(2)) for 4 days, and CY 50 mg/kg on days +3 and +4 after BM or peripheral blood (PB) transplantations from matched related (MRD) or unrelated donors (MUD). MUD recipients received antithymocyte globulin (ATG); however, a later amendment removed ATG. Forty-nine patients were treated (acute myeloid leukemia/myelodysplastic syndrome, 82%). Median age was 62 years (range, 39 to 72). Fifteen patients received an MRD (9 PB/6 BM); 34 had a MUD (2 PB/32 BM). The cumulative incidence of grade II to IV acute GVHD, III to IV acute GVHD, and chronic GVHD was 58%, 22%, and 18%, respectively. A matched cohort analysis compared outcomes to tacrolimus/methotrexate GVHD prophylaxis and indicated higher rates of acute GVHD grade II to IV (46% versus 19%; hazard ratio [HR], 2.8; P = .02) and treatment-related mortality (HR, 3.3; P = .035) and worse overall survival (HR, 1.9; P = .04) with post-CY. The incidence of chronic GVHD and CMV reactivation did not differ. This study suggests that post-CY should not be used as sole GVHD prophylaxis after a RIC transplantation from HLA-matched donors.

Keywords: Acute; Chronic; Graft-versus-host disease; Marrow; Stem cell transplantation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of Acute GVHD II–IV (a), Acute GVHD III/IV (b), Non-Relapse Mortality (c), Relapse (d) and Over-all Survival (e)in Recipients of GVHD Prophylaxis with Post-Cy (hashed line) and Tacrolimus/Methotrexate (solid line) following RIC allogeneic transplants from MRD and MUD’s
Figure 1
Figure 1
Comparison of Acute GVHD II–IV (a), Acute GVHD III/IV (b), Non-Relapse Mortality (c), Relapse (d) and Over-all Survival (e)in Recipients of GVHD Prophylaxis with Post-Cy (hashed line) and Tacrolimus/Methotrexate (solid line) following RIC allogeneic transplants from MRD and MUD’s
Figure 1
Figure 1
Comparison of Acute GVHD II–IV (a), Acute GVHD III/IV (b), Non-Relapse Mortality (c), Relapse (d) and Over-all Survival (e)in Recipients of GVHD Prophylaxis with Post-Cy (hashed line) and Tacrolimus/Methotrexate (solid line) following RIC allogeneic transplants from MRD and MUD’s
Figure 1
Figure 1
Comparison of Acute GVHD II–IV (a), Acute GVHD III/IV (b), Non-Relapse Mortality (c), Relapse (d) and Over-all Survival (e)in Recipients of GVHD Prophylaxis with Post-Cy (hashed line) and Tacrolimus/Methotrexate (solid line) following RIC allogeneic transplants from MRD and MUD’s
Figure 1
Figure 1
Comparison of Acute GVHD II–IV (a), Acute GVHD III/IV (b), Non-Relapse Mortality (c), Relapse (d) and Over-all Survival (e)in Recipients of GVHD Prophylaxis with Post-Cy (hashed line) and Tacrolimus/Methotrexate (solid line) following RIC allogeneic transplants from MRD and MUD’s
See this image and copyright information in PMC

References

    1. Alousi AM, Bolanos-Meade J, Lee SJ. Graft-versus-host disease: state of the science. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2013;19(1 Suppl):S102–108. doi: 10.1016/j.bbmt.2012.10.028. - DOI - PMC - PubMed
    1. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nature medicine. 1999;5(11):1298–1302. doi: 10.1038/15256. e-pub ahead of print 1999/11/05. - DOI - PubMed
    1. Fischer AC, Ruvolo PP, Burt R, Horwitz LR, Bright EC, Hess JM, et al. Characterization of the autoreactive T cell repertoire in cyclosporin-induced syngeneic graft-versus-host disease. A highly conserved repertoire mediates autoaggression. Journal of immunology (Baltimore, Md: 1950) 1995;154(8):3713–3725. e-pub ahead of print 1995/04/15. - PubMed
    1. Beschorner WE, Hess AD, Shinn CA, Santos GW. Transfer of cyclosporine-associated syngeneic graft-versus-host disease by thymocytes. Resemblance to chronic graft-versus-host disease. Transplantation. 1988;45(1):209–215. e-pub ahead of print 1988/01/01. - PubMed
    1. Jenkins MK, Schwartz RH, Pardoll DM. Effects of cyclosporine A on T cell development and clonal deletion. Science. 1988;241(4873):1655–1658. - PubMed

Publication types

MeSH terms